This article is more than 5 years old. Information may no longer be current.

FDA approves generic combo HIV- 1 drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has approved a generic version of the combination lamivudine and zidovudine tablets for the treatment of HIV-1 infection, according to an FDA press release.

The 150 mg and 300 mg tablets will be manufactured by Aurbindo Pharma Limited of Hyderabad, India and is indicated for use in combination with other antiretroviral therapies for the treatment of HIV-1.

“The FDA has determined that the generic is bioequivalent and therapeutically equivalent to the reference drug (Combivir, GlaxoSmithKline). The approval means that the generic formulation may be marketed in the United States,” according to the release.